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ABSTRACT 
Background and Aim:  The aim of this study was to illustrate the present role of transsphenoidal surgery as 
primary therapy in GH – secreting adenomas. The present study was undertaken to assess the effect of surgical 
removal of adenoma on peripheral adenohypophyseal hormones. In addition, the pituitary hormones have also 
been measured directly in the adenoma tissue following its surgical removal. 
Methods:  The present study is based on 07 patients (04 males and 3 females), 30-50 year of age, diagnosed for 
Functional Pituitary Adenomas (FPAs) on the basis of clinical and radiological evidence. An equal number of 
age matched healthy subjects were included as controls. Follicle stimulating hormone (FSH), thyroid stimulating 
hormone (TSH), growth hormone (GH) and prolactin (PRL) were determined in serum before and following 
trans-sphenoidal adenomectomy. The GH, FSH, TSH and PRL content of the excised adenoma tissue was also 
measured in male patients. All hormone determinations were carried out using commercially available immuno-
assay kits (ELISA and IRMA) in duplicate. 
Results:  The results demonstrate that the mean serum GH levels in the 04 male and 03 female patients with FPAs 
were found to be significantly higher before surgical removal as compared to those obtained following surgery. 
Significant differences were observed between pre- and postsurgical serum GH levels in male and female patients 
with FPA. GH content was also determined in the male adenoma tissue. Following removal of the adenoma in 
these 4 male and 03 female patients, peripheral serum GH levels fell within the normal range. The adenoma 
tissue GH content in patients with initial higher serum GH levels was also significantly greater than that of the 
other patients. The mean serum PRL concentration in male patients before removal of the adenoma and values 
obtained after surgical removal of the adenoma and those of control subjects were not significantly different. The 
mean PRL concentration of the adenoma tissue in all the male patients was not significantly different from the 
control pituitary tissue. However, the presurgical mean serum PRL concentration were significantly higher in 2 of 
the 3 female patients included in this study as compared to the control values. Following removal of adenoma, 
normal serum levels were attained in those patients. In the remaining one female patient serum PRL concentra-
tion was within the normal range before and following surgical removal of the adenoma. The mean serum FSH 
levels in the 04 male patients with FPAs were not significantly different before and after surgical removal of ade-
noma tissue. However, an examination of individual values reveals higher FSH levels in 02 of the male patients 
and in 01 of the three premenopausal female patients. Following surgical removal of the adenoma, serum FSH 
concentrations showed a marked decline of FSH levels in those patients. However, the remaining two females 
showed normal FSH levels before and after surgery. The adenoma FSH content of these patients was not signifi-
cantly higher than those of the control pituitary tissue. No significant differences were observed between pre and 
post-surgical serum TSH levels. The TSH content of adenoma tissue was either non-detectable or in the low range 
as compared to the TSH content determined in control pooled pituitary tissue. 
Conclusion:  Transsphenoidal surgery is thought to be an effective primary treatment for GH-secreting pituitary 
adenomas according to the most recent criteria of cure. Because the remission rate in cases with cavernous sinus 
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invasion is very low, early detection of the tumor before it extends into the cavernous sinus and a long-term 
endocrinological and radiological follow-up are necessary in order to improve the remission rate of acromegaly. 
Keywords:  Acromegaly, Insulin-like growth factor I, Pituitary adenoma, Surgical outcome. 
 
INTRODUCTION 
Acromegaly is a rare but very serious condition usua-
lly caused by a growth hormone (GH) – producing pit-
uitary adenoma. Although acromegaly is an uncom-
mon disease, the average incidence rate being reported 
as 3.1 to 3.8 / million inhabitants / year. The estimated 
prevalence of the disease is 40 cases / 1000000 popu-
lation with 3 – 4 new cases / 1000000 population per 
year. Over 95% of acromegalic patients have GH 
excess due to a GH – producing pituitary adenoma, 
and surgical excision of the adenoma has been con-
sidered the most reliable therapy to restore GH abnor-
mal response to normal.
1,5
 
 Ectopic GH or GH-releasing hormone production 
or a pituitary carcinoma may very infrequently also 
cause acromegaly. Several retrospective cohort studies 
suggest that mortality in acromegaly is at least twice of 
that in the general population.
1–4
 The cause of death is 
most commonly a vascular accident, but significant 
increases have been reported for both respiratory dis-
orders and malignancies. These studies have also 
demonstrated that a reduction of GH levels significan-
tly lowered mortality and that mortality rates similar to 
those of the general population are restored once re-
mission is induced. Partial reduction of GH levels has 
been proven to be inadequate to restore normal life 
expectancy.
1,5
 Therefore, aggressive management to 
lower serum GH levels is necessary once the diagnosis 
has been confirmed. Depot somatostatin analogues are 
now increasingly being prescribed in acromegaly. 
 Studies have shown them to be both effective and 
safe with endocrinological remission in up to 60% of 
cases.
6–9
 The newly developed GH receptor antagonist 
pegvisomant seems to be able to normalise insulin – 
like growth factor (IGF)-I in up to 97% of patients and 
may become an important therapeutic option in acro-
megaly.
10,11
 However, the most recent consensus gui-
delines for the management of acromegaly suggest for 
the majority of patients surgery as the first – line the-
rapy, either alone or in combination with medical tre-
atment, conventional radiotherapy and / or radiosur-
gery.
12
 
 The aim of this study was to update the surgical 
results in a series of acromegalic patients treated in the 
Department of Neurosurgery at the Lahore General 
Hospital, Lahore. We analyzed the surgical outcome 
by comparing the GH, FSH, TSH and Prolactin level 
before and after surgery in 07 consecutive acromegalic 
patients undergoing Transsphenoidal surgery for the 
treatment of GH – producing adenomas at Lahore 
General Hospital during 2005 to 2007, in order to reas-
sess the efficacy of transsphenoidal surgery for this 
disorder. 
 
MATERIALS AND METHODS 
The present study initially included 07 patients 04 men 
and 3 women, of 22 – 55 (44 ± 2.3) years of age with 
NFPAs. All patients underwent pituitary tumour sur-
gery. The adenoma was removed in all 07 patients 
through transsphenoidal route. All cases were operated 
at the Department of Neurosurgery, Lahore General 
Hospital, Lahore. 
 The study also included 07 sex and age matched 
healthy subjects that served as the control group with 
22 – 55 years of age. The subjects fulfilling inclusion 
criteria were enrolled in the study after obtaining his / 
her written informed consent. The study was approved 
by the Ethical Committee and the Advanced Studies 
and Research Board of the University of Health Scien-
ces, Lahore. 
 Blood samples from patients with pituitary adeno-
mas were obtained prior to surgery and 2 months after 
removal of the pituitary adenoma. Blood samples were 
also obtained from an equal number of age and sex 
matched control subjects for purposes of comparison. 
Five ml of blood sample were drawn from each patient 
and blood was centrifuged at 3,000 rpm for 10 – 15 
minutes to separate serum and aliquoted in two por-
tions and stored at -30
o 
C until analyzed. 
 The pituitary adenoma tissue was divided into two 
parts. One part was fixed in buffered formalin and 
processed for histological examination, whereas the 
other half was weighed and homogenized in ice-cold 
phosphate buffer saline (PBS), at a dilution of approxi-
mately 50 mg/ml. The samples were centrifuged for 30 
min at 10000 rpm and the supernatant was frozen at -
30 C. Pituitary tissue was also obtained from three 
adult males at the post-mortem examination, pooled 
and processed identically as the adenoma tissue for 
extraction. Pituitary tissue from female controls could 
not be made available. 
Saba Khalid et al 
-72-         Pak. J. of Neurol. Surg. – Vol. 15, No. 2, Jul. – Dec., 2011 
 Following fixation, adenoma tissue was processed 
for histopathological examinations. Paraffin sections 
of the tissue were cut at a thickness of 3 – 5 µm and 
stained routinely with hemotoxylin and counterstained 
with eosin. 
 
Hormone Determinations 
Serum FSH, TSH, GH, PRL were determined by ELI-
SA in duplicate using standard procedures with com-
mercially available assay kits with an automated EIA 
analyzer. Hormone content of adenoma and pituitary 
tissue, was measured with a specific radiometric assay 
in the extract obtained, by commercially available 
IRMA kits with an automated gamma counter (Perkin 
Elmer, Turku, Finland). 
Statistical Analysis 
The significance of differences among different groups 
was analyzed by one way analysis of variance {ANO-
VA} followed by Duncan’s multiple t-test. P value of 
<0.05 was considered statistically significant. All cal-
culations were carried out with the SPSS version 12 
(SPSS Inc, Chicago, IL, USA). 
 
RESULTS 
Growth Hormone 
The mean serum GH levels in the 04 male patients 
with FPAs were found to be significantly higher (P < 
0.05) before surgical removal as compared to those 
obtained following surgery (30.2 ± 3.1 vs 4.4 ± 1.5
 
Table 1: Mean ± SEM serum GH levels and GH content of adenoma 
tissue, in male and female patients with FPA and in normal 
subjects. 
 
Group 
Serum GH 
(ng/ml) 
Adenoma tissue 
GH (ng/ml) 
Males 
Control Subjects (n = 04) 
  0.4 ± 0.1  
Patients with pituitary adenoma (n = 04)  17939 
 Presurgical 30.2 ± 3.1*  
 Postsurgical   4.4 ± 1.5  
Pooled pituitary tissue  102.9 
Females 
Control Subjects (n = 03) 
  0.2 ± 0.06  
Patients with pituitary adenoma (03)   
 Presurgical 38.9 ± 10.3*  
 Postsurgical   5.7 ± 4.8  
 
*Significantly different from postsurgical and control value (P < 0.05; ANOVA 
followed by Duncan’s t- test). 
ng/ml) as shown in (Table 1). How-
ever, an examination of individual 
values reveals that the observed 
higher mean levels of GH prior to 
surgery were almost 4 – fold of the 
control levels (> 7 ng/ml or less) as 
shown in Tables 1 and 2. Signifi-
cant differences were observed bet-
ween pre- and postsurgical serum 
GH levels in male and female pati-
ents with FPA (Tables 7). GH con-
tent was also determined in the 
male adenoma tissue. The adenoma 
tissue content of GH of the male 
patients is also given in Table 1. As 
may be noted, the adenoma GH 
content in patients with the initial 
higher peripheral concentrations, 
was also markedly greater (P<0.05) 
than that of the control pituitary 
tissue. 
 
Table 2:  Serum GH levels in male patients with FPA and in age-matched control subjects. 
 
Patients with FPA Control subjects 
 Patient ID Age (y) 
GH (ng/ml) Patient ID Age (y) 
Serum Control 
GH (ng/ml) 
Presurgical Postsurgical    
Males PA1 40 31.3 1.4 C1 35 0.09 
 PA2 42 22.2 3.5 C2 42 0.2 
 PA3 35 37.5 8.6 C3 35 0.4 
 PA4 32 29.8 4.3 C4 32 0.9 
a 
b 
b 
a 
a 
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Table 3:  Serum GH levels in female patients with FPA and in age-matched control subjects. 
 
Patients with FPA Control subjects 
 Patient ID Age (y) 
GH (ng/ml) Patient ID 
Age 
(y) 
Serum Control 
GH (ng/ml) 
Presurgical Postsurgical    
Females        
 PA5 23 33.6 15.3 C5 23 0.1 
 PA6 35 58.7 0.8 C6 35 0.2 
 PA7 50 24.2 0.9 C7 50 0.2 
 
Prolactin 
The mean serum PRL concentra-
tion in male patients before remo-
val of the adenoma and values ob-
tained after surgical removal of the 
adenoma and those of control sub-
jects were not significantly diffe-
rent (Table 4 and 5). The patients 
serum PRL concentrations were 
within the normal limit of circulat-
ing PRL levels (<17.0 ng/ml). The 
individual and mean serum PRL 
levels in the male patients were in 
normal range before and after sur-
gery. The mean PRL concentration 
of the adenoma tissue in all the 
male patients was not significantly 
different from the control pituitary 
tissue. 
 However, the presurgical mean 
serum PRL concentration were sig-
nificantly higher in 2 of the 3 fema-
le patients included in this study as 
compared to the control values. 
Following removal of adenoma, 
 
Table 4: Mean ± SEM serum PRL levels and PRL content of adenoma 
tissue, in male and female patients with FPA and normal 
subjects. 
 
Group 
Serum PRL 
(ng/ml) 
Adenoma tissue 
PRL Content 
(ng/g) 
Males 
Control Subjects (n = 04) 
  5.5 ± 0.5  
Patients with pituitary adenoma  11.4 
 Presurgical 10.9 ± 2.7  
 Postsurgical   7.5 ± 2.2  
Pooled pituitary tissue    1.8 
Females 
Control Subjects (n = 03) 
5.7 ± 0.2  
Patients with pituitary adenoma (n = 03)   
 Presurgical 32.8 ± 6.9*  
 Postsurgical 15.1 ± 1.7  
 
*Significantly different from postsurgical and control value (P < 0.05; ANOVA 
followed by Duncan’s t- test). 
 
 
Table 5:  Serum PRL levels in male patients with FPA and in age-matched control subjects. 
 
Patients with FPA Control subjects 
 Patient ID Age (y) 
PRL (ng/ml) Patient 
ID 
Age 
(y) 
Serum Control 
PRL (ng/ml) Presurgical Postsurgical 
Males PA1 40 18.4 10.2 C1 35 6.7 
 PA2 42   6.1   3.4 C2 42 6.1 
 PA3 35 11.5 12.6 C3 35 4.3 
 PA4 32   7.8   4.0 C4 32 5.0 
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Table 6:  Serum PRL levels in female patients with FPA and in age-matched control subjects. 
 
Patients with NFPA Control subjects 
 Patient ID Age (y) 
PRL (ng/ml) Patient 
ID 
Age 
(y) 
Serum Control 
PRL (ng/ml) Presurgical Postsurgical 
Females PA5 23 26.9   6.4 C5 23 5.2 
 PA6 35 61.4 10.1 C6 35 5.7 
 PA7 50 10.1   4.3 C7 50 6.1 
 
normal serum levels were attained 
(Table 6). In the remaining one fe-
male patient serum PRL concentra-
tion was within the normal range be-
fore and following surgical removal 
of the adenoma. 
 
Follicle Stimulating Hormone 
The mean serum FSH levels in the 04 
male patients with FPAs were not 
significantly different before and after 
surgical removal of adenoma tissue 
(Table 7). However, an examination 
of individual values reveals higher 
FSH levels in 02 of the male patients. 
In these subjects serum FSH concent-
rations returned to the normal range 
following removal of the adenoma as 
shown in Tables 8. The adenoma FSH 
content of these patients was not sig-
nificantly higher than those of the 
control pituitary tissue. 
 In 01 of the three premenopausal 
female patients included in the study,
 
Table 7: Mean ± SEM serum FSH levels and FSH content of adenoma 
tissue, in male and female patients with FPA and normal 
subjects. 
 
Group 
Serum FSH 
(mIU/ml) 
Adenoma tissue 
FSH Content 
(IU/g) 
Males 
Control Subjects (n = 04) 
  8.09 ± 0.8  
Patients with pituitary adenoma  2.5 
 Presurgical 10.57 ± 3.08  
 Postsurgical 16.4 ± 9.61  
Pooled pituitary tissue  10.6 
Females 
Control Subjects (n = 03) 
  8.4 ± 1.7  
Patients with pituitary adenoma (03)   
 Presurgical 16.3 ± 9.3*  
 Postsurgical   7.9 ± 1.6  
 
*Significantly different from postsurgical and control value (P < 0.05; 
ANOVA followed by Duncan’s t- test). 
 
 
 
Table 8:  Serum FSH levels in male patients with FPA and in age – matched control subjects. 
 
Patients with FPA Control subjects 
 
Patient 
ID 
Age 
(y) 
FSH (mIU/ml) Patient 
ID 
Age 
(y) 
Serum Control 
FSH (mIU/ml) Presurgical Postsurgical 
Males PA1 40   5.4 4.9 C19 35   07 
 PA2 42 19.5 8.6 C17 42   6.3 
 PA3 35   8.4 9.05 C18 35   8.9 
 PA4 32 19.2 8.2 C19 32 10.0 
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Table 9:  Serum FSH levels in female patients with FPA and in age-matched control subjects. 
 
Patients with NFPA Control subjects 
 
Patient 
ID 
Age 
(y) 
FSH (mIU/ml) 
Patient 
ID 
Age 
(y) 
Serum Control 
FSH (mIU/ml) 
Presurgical Postsurgical 
Females PA5 23 7.8   6.4 C17 23 7.07 
 PA6 35 6.05   6.2 C18 35 11.8 
 PA7 50 35.02 11.2 C19 50 6.3 
 
the serum FSH was significantly 
higher than of the control as shown 
in Table 9. Following surgical re-
moval of the adenoma, serum FSH 
concentrations showed a marked 
decline of FSH levels in that pati-
ent. However, the remaining two 
females showed normal FSH levels 
before and after surgery. 
 
Thyroid Stimulating Hormone 
The presurgical mean serum TSH 
concentrations in male and female 
patients with pituitary adenoma 
were mostly in the lower range and 
were not significantly different 
from levels following removal of 
the adenoma and of the control sub-
jects. The TSH content of male 
adenoma tissue was either in the 
non-detectable range of the assay 
or comparable to the control pitui-
tary tissue (Table 10). 
 
 
Table 10: Mean ± SEM serum TSH levels and TSH content in adenoma 
tissue, in male and female patients with FPA and normal 
subjects. 
 
Group 
Serum TSH 
(µIU/ml) 
Adenoma tissue 
TSH Content 
(µIU/ml) 
Males 
Control Subjects (n = 04) 
1.7 ± 1.4  
Patients with pituitary adenoma (n = 04)    1.4 
 Presurgical 0.3 ± 0.1  
 Postsurgical 0.4 ± 0.1  
Pooled pituitary tissue  14.5 
Females 
Control Subjects (n = 03) 
0.3 ± 0.1  
Patients with pituitary adenoma (03)   
 Presurgical 1.2 ± 0.8  
 Postsurgical 0.6 ± 0.4  
 
 
Table 11:  Serum TSH levels in male patients with FPA and in age-matched control subjects. 
 
Patients with FPA Control subjects 
 Patient ID Age (y) 
TSH (µIU/ml) 
Patient 
ID 
Age 
(y) 
Serum Control 
TSH (µIU/ml) 
Presurgical Postsurgical 
Males PA1 40 0.2 0.1 C19 35 6.0 
 PA2 42 0.3 0.9 C17 42 0.1 
 PA3 35 0.1 0.2 C18 35 0.1 
 PA4 32 0.6 0.4 C19 32 0.6 
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Table 12:  Serum TSH levels in female patients with FPA and in age-matched control subjects. 
 
Patients with NFPA Control subjects 
 
Patient 
ID 
Age 
(y) 
TSH (µIU/ml) Patient 
ID 
Age 
(y) 
Serum Control 
TSH (µIU/ml) Presurgical Postsurgical 
Females PA5 23 0.3 0.2 C17 23 0.5 
 PA6 35 0.5 0.3 C18 35 0.3 
 PA7 50 2.8 1.4 C19 50 0.1 
 
DISCUSSION 
In the present study, we have attempted to assess the 
hormonal contribution of the pituitary adenomas diag-
nosed as functioning, by measuring pituitary hormones 
in serum before and after surgical removal of the tum-
our, and in the excised adenoma tissue. Our results 
indicate that the production and release of GH, occurs 
in all acromegalic patients. In the present study a hy-
persecretion of GH was evident in 4 male and 3 female 
patients. These observations are further supported by 
the finding that the GH content of the adenoma tissue 
of these patients was significantly higher than those of 
the control pituitary tissue. In this study, we observed 
a significant positive correlation between post-surgical 
GH levels after transsphenoidal surgery (TSS), sug-
gesting that lower GH levels in the early postoperative 
period are a good predictive marker. These findings 
are consistent with previous reports.
5,6
 
 In some previous studies, FPAs have been shown 
to secrete adenohypophysial hormones, most com-
monly PRL.
21,25
 In our study, we have observed nor-
mal PRL levels in male patients before and after sur-
gical removal of the adenoma. However, the presurgi-
cal mean serum PRL concentration were significantly 
higher in 2 of the 3 female patients included in this 
study as compared to the control values. Following 
removal of adenoma, normal serum levels were attai-
ned. These observations are supported by the finding 
that the adenoma PRL content in patients with the ini-
tial higher peripheral concentrations, was also mar-
kedly greater (P < 0.05) than that of the patients with 
normal serum PRL levels and the control pituitary tis-
sue. 
 Similarly, higher FSH levels were found in 02 of 
the male patients and 01of the three premenopausal 
female patients included in the study, the mean value 
was significantly higher than of the control. Following 
surgical removal of the adenoma, serum FSH concent-
rations showed a marked decline of FSH levels in 
those patients. FSH content of the adenoma tissue of 
these patients was not significantly higher than those 
of the control pituitary tissue. Other studies have repo-
rted a low incidence of elevated gonadotropins in pati-
ents with FPAs and these results are generally consis-
tent with our findings.
4,7-11
 
 In our study, the presurgical mean serum TSH 
concentrations in patients with pituitary adenoma were 
mostly in the lower range and were not significantly 
different from the control. No significant differences 
were observed in TSH levels before and following 
removal of the adenoma. Other studies have also 
reported low or normal TSH levels in patients with 
FPAs and are generally consistent with our find-
ings.
13,14
 
 In our study, we have analyzed the surgical results 
of TSS for acromegaly focusing on patients with bio-
chemical and clinical follow-up data. Preoperative data 
such as age and sex distribution, tumor, preoperative 
GH concentration were comparable with those from 
other studies.
1,3,14,21
 
 An endocrinological “cure” for acromegaly, as 
defined by the stringent criteria of biochemical remis-
sion,
10,21
 was achieved in 100% of patients, similar to 
that reported in the most recent series.
16,19-21,25
 TSS 
remains an effective treatment for acromegaly, whe-
reas medical treatment and / or radiotherapy should be 
reserved for patients with persistent GH / IGF-I hyper-
secretion after surgery.
4
 
 TSS of GH – secreting pituitary adenoma conti-
nues to be a safe and effective method for dealing with 
a large number of patients with acromegaly. The goal 
of overall management should be to provide the pati-
ent with the most effective means of long term control 
of this benign but potentially disabling disease. 
 The limitation of this study is being short study 
duration in small number of patients. Therefore, a pro-
spective study in more patients will be necessary to 
further evaluate the factors affecting the remission rate 
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of acromegaly. It is hoped that with advances in phar-
macotherapy, surgical treatment may become even 
more focused, more precise and more effective over 
time. 
 
CONCLUSION 
This article gives an insight on the treatment of acro-
megaly, especially on adenomas invading the caver-
nous sinus. On the basis of recent remission criteria, 
our series demonstrate the good efficacy of TSS for 
acromegalic patients with microadenomas and non-
invasive macroadenomas. In patients with larger tum-
ors, cavernous sinus invasion or high preoperative GH 
levels, the remission rate is lower. Therefore, early 
detection of the tumor and a long-term endocrinologi-
cal and radiological follow-up may improve the remis-
sion rate of acromegaly. However, this study only in-
vestigated changes in GH, PRL, FSH and TSH serum 
levels and over a short postoperative period. Long – 
term observation is needed to confirm whether the cur-
rent criteria can predict long – term disease activity 
accurately in patients with acromegaly. 
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